Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. - Wikidata - awgldk - TriplyDB

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

http://www.wikidata.org/entity/Q34531086

about

Immunotoxicity of monoclonal antibodies Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols Oral TNFα Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model Regulation of tumour necrosis factor signalling: live or let die A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.Increased survival after gemfibrozil treatment of severe mouse influenza.Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature.Rationale of using different biological therapies in rheumatoid arthritis.Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice Update of the management of chronic psoriasis: new approaches and emerging treatment options.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.ADAM17-mediated processing of TNF-α expressed by antiviral effector CD8+ T cells is required for severe T-cell-mediated lung injury.Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection Novel biological immunotherapies for psoriasis.The occurrence and prevention of foodborne disease in vulnerable people.Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis.Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis.Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis.Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 ASAS/EULAR recommendations for the management of ankylosing spondylitis.Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.Etanercept: a clinical review of current and emerging indications.Pathogenesis of malaria and clinically similar conditions.Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis.Biologics in combination with nonbiologics: efficacy and safety.The safety of etanercept for the treatment of plaque psoriasis.Serious infections associated with anticytokine therapies in the rheumatic diseases.

P2860

Q24653374-4D72B344-216F-4B3D-83AD-D951E5D54DBF Q24673716-A2C4F303-47C3-4380-B140-9310A3253EFA Q24793159-D004817B-AD16-4F30-85FC-70121DA55C10 Q27319559-AF4FCBD6-8CC5-4F05-99D9-F36A97358E0C Q28262381-33687150-D25D-4CAD-9D63-01D7DCD10E80 Q28282330-09C17E07-EC2E-4BCE-966B-CE57CF9A001B Q33213561-EAC19DFC-E7FD-46F1-944D-B1609E196964 Q33222422-156D5F1C-2640-4631-A8DE-974B8B16229A Q33315300-F8D0F11C-0638-44F6-B5AF-36B5C3E3F9EC Q33371653-E3D0F074-8978-4F6D-9C61-6398056569AE Q33819684-B8FF04A6-093D-402C-B030-F1B49792C9EB Q33845259-449E5920-48B5-4EE5-B6D2-58979D7E72D2 Q33859169-083219C7-03B9-4A97-9A7A-171FB6C19118 Q34153073-94212FBD-4560-4384-96E4-F0F6CBFA5D49 Q34250544-A8E97823-087A-4C7B-9A1D-51091A9CA578 Q34620375-D0C4C266-1E5C-4FEF-82E0-7CD8663C986D Q35026302-8AFD9708-A3B7-4172-9611-995F2D380712 Q35040269-6405E503-D7AF-44DC-8541-E10C2DA9E7E2 Q35131219-98B031E1-8A37-4A1F-8BA6-DC4BBBB6AA7F Q35164740-2ED6693C-E8CB-44BC-9A06-7DFA162D0E0B Q35173590-0E481AE4-B79A-4106-B6EC-01780793B313 Q35194346-235EAEDA-03B5-4E6A-8513-B6CD749CE55C Q35216972-41EAD27C-872B-4819-8E5E-C7CFB2882C2C Q35237588-A44A05E4-3D46-4A23-860A-EEC50C48F0BC Q35553451-EA645AD3-F06C-4CED-BC29-C3B959F1AC5A Q35553478-35BFE442-E297-411F-BCCE-A154BC0E7B86 Q35567825-5C525785-32CF-4346-8A27-7B73C355E8F1 Q35579352-36C69165-76A8-41BF-A990-AA80BF1F7C6B Q35579517-4C8588DA-57E0-4894-BB03-A42BC6850100 Q35637012-1FDD2289-8A0B-46C6-ACE3-14501D116720 Q35637343-25CE96C9-051F-4059-9744-F4B0A4833D6E Q35638252-BEA319CB-3BDE-475F-911D-27597BF8188D Q35688168-1D925411-2747-4F68-841A-72F49E710595 Q35705082-6968B330-5891-4D7E-B693-6B43315D2C5D Q35779227-A4D43171-BF54-46D8-BD99-46AB4938D273 Q35838590-9FA40EAA-1A19-47E2-BBED-77121FF286E1 Q35842626-2B94D76C-61D7-4B91-B852-9F346F8E6398 Q35893172-E5EB6003-714F-4F53-B6BD-F0F275F48A2D Q35919214-AA0BF249-D149-4C32-BC5D-A7729E8C97C5 Q35937819-5F12F080-D63F-446F-A4CC-ACC6B49F7F0B

P2860

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

http://www.wikidata.org/entity/Q34531086

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@ast

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@en

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@nl

type

label

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@ast

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@en

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@nl

prefLabel

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@ast

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@en

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@nl

P1433

Q34531086-411C9DC5-66D8-4AA2-ADA4-8EF193707844

P1476

Q34531086-F020D620-934B-45C1-AF1C-5F2446FE548D

P2093

Q34531086-20AC41BE-4C89-428E-8EC1-7A7E6222C0DA

Q34531086-43729AD3-DF60-4FA1-982C-E2D776D08A16

Q34531086-93199D1A-5A71-4DA8-B2A3-07DED130C49E

Q34531086-BA6280B5-F93B-49B5-AC9A-775D73404A4D

Q34531086-D8B7A059-E125-43B1-851B-ED027DC5BB9F

P304

Q34531086-1124DEB7-2E16-433D-B8BF-6B1ADF175F0C

P31

Q34531086-2250DE52-56E1-4A43-A163-7B4667802BF7

P356

Q34531086-01B96052-A890-4EC9-9F5F-4CFA15A61DF1

P433

Q34531086-E8508062-AD6E-40ED-9F85-0FC7BA707CC3

P478

Q34531086-AB31AA2D-AAD4-434B-B288-5222629137FD

P577

Q34531086-811893DC-56E4-46DF-BF13-9268522A4B8B

P698

Q34531086-F4DDFC77-999E-433D-B582-D557AAACD6B1

P921

Q34531086-4C8AD003-2DDE-419D-BE07-3A371226363F

P356

P1433

Arthritis & Rheumatology

P1476

Listeria monocytogenes infecti ...... tor alpha-neutralizing agents.

@en

P2093

Evelyne T Edwards

http://www.w3.org/2001/XMLSchema#string

Jong-Hoon Lee

http://www.w3.org/2001/XMLSchema#string

M Miles Braun

http://www.w3.org/2001/XMLSchema#string

Nancy R Slifman

http://www.w3.org/2001/XMLSchema#string

Sharon K Gershon

http://www.w3.org/2001/XMLSchema#string

P304

319-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.10758

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12571839

http://www.w3.org/2001/XMLSchema#string

P921

Listeria monocytogenes